BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

LGND

Ligand Pharmaceuticals Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$79M−31.8% year on year
$150M$100M$50M$0
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 30 Oct 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

91.9%−6.1 pp year on year
100%95%90%85%
Q4 ’14Q1 ’16Q2 ’17Q2 ’18Q3 ’19
Company filings · 10-K filed 24 Feb 2021 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$56M−59.9% year on year
$1.5B$1B$500M$0
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 30 Oct 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$91M+194.6% year on year
$150M$100M$50M$0
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 30 Oct 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty